Identification of factors conferring resistance to trastuzumab deruxtecan in advanced gastric cancer: a translational study from the single-arm, phase II, DESTINY-Gastric06 trial.
[BACKGROUND] Trastuzumab deruxtecan (T-DXd) has revolutionized the therapeutic landscape for HER2-positive gastric cancer (GC).
APA
Zhang B, Zhang L, et al. (2026). Identification of factors conferring resistance to trastuzumab deruxtecan in advanced gastric cancer: a translational study from the single-arm, phase II, DESTINY-Gastric06 trial.. Precision clinical medicine, 9(1), pbaf038. https://doi.org/10.1093/pcmedi/pbaf038
MLA
Zhang B, et al.. "Identification of factors conferring resistance to trastuzumab deruxtecan in advanced gastric cancer: a translational study from the single-arm, phase II, DESTINY-Gastric06 trial.." Precision clinical medicine, vol. 9, no. 1, 2026, pp. pbaf038.
PMID
41625230
Abstract
[BACKGROUND] Trastuzumab deruxtecan (T-DXd) has revolutionized the therapeutic landscape for HER2-positive gastric cancer (GC). However, tumor heterogeneity poses a significant challenge in overcoming T-DXd resistance. This study aimed to delineate the mechanisms underlying primary and acquired resistance to T-DXd in GC.
[METHODS] We performed single-cell RNA sequencing on GC tumor tissues from the DESTINY-Gastric06 study, including treatment-naive baseline samples and those with primary or acquired resistance to T-DXd. Dimensionality reduction and unsupervised clustering were applied to identify distinct cell clusters within the tumor tissues. High-dimensional weighted gene co-expression network analysis was employed to identify key gene modules associated with T-DXd resistance. Cell-cell communication was analyzed using CellChat. Key findings were experimentally validated through multiplex immunofluorescence, immunohistochemistry, and functional assays in cellular models.
[RESULTS] Weighted gene co-expression network analysis identified the red and purple modules as being strongly correlated with primary and acquired T-DXd resistance, respectively. Notably, MUC3A was upregulated in patients with primary resistance and its overexpression was identified as a potential predictor of shorter progression-free survival in response to T-DXd therapy. Moreover, cystatin C, a gene implicated in linker cleavage, was upregulated during the development of acquired resistance. Tumor microenvironment profiling revealed that T-DXd initially promoted immune-cell infiltration and enhanced antigen presentation. However, with the development of resistance, the tumor microenvironment shifted to an immunosuppressive state, characterized by reactivation of transforming growth factor-beta signaling and upregulation of programmed cell death protein-1 (PD-1).
[CONCLUSION] These findings provide novel insights into mechanisms underlying T-DXd resistance and highlight potential therapeutic targets for overcoming T-DXd resistance in GC.
[METHODS] We performed single-cell RNA sequencing on GC tumor tissues from the DESTINY-Gastric06 study, including treatment-naive baseline samples and those with primary or acquired resistance to T-DXd. Dimensionality reduction and unsupervised clustering were applied to identify distinct cell clusters within the tumor tissues. High-dimensional weighted gene co-expression network analysis was employed to identify key gene modules associated with T-DXd resistance. Cell-cell communication was analyzed using CellChat. Key findings were experimentally validated through multiplex immunofluorescence, immunohistochemistry, and functional assays in cellular models.
[RESULTS] Weighted gene co-expression network analysis identified the red and purple modules as being strongly correlated with primary and acquired T-DXd resistance, respectively. Notably, MUC3A was upregulated in patients with primary resistance and its overexpression was identified as a potential predictor of shorter progression-free survival in response to T-DXd therapy. Moreover, cystatin C, a gene implicated in linker cleavage, was upregulated during the development of acquired resistance. Tumor microenvironment profiling revealed that T-DXd initially promoted immune-cell infiltration and enhanced antigen presentation. However, with the development of resistance, the tumor microenvironment shifted to an immunosuppressive state, characterized by reactivation of transforming growth factor-beta signaling and upregulation of programmed cell death protein-1 (PD-1).
[CONCLUSION] These findings provide novel insights into mechanisms underlying T-DXd resistance and highlight potential therapeutic targets for overcoming T-DXd resistance in GC.
같은 제1저자의 인용 많은 논문 (5)
- Deliberately Staged Combined Endovascular Embolization and Subsequent Microsurgery Resection for the Treatment of Cerebral Arteriovenous Malformations.
- Next-generation dynamic and combinatorial nanotherapies for liver cancer: mechanisms, current advances and future perspectives.
- A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS.
- Sanguinarine Antagonizes NSCLC Through PPARG-Mediated PI3K/AKT Suppression and Autophagic Apoptosis.
- Preoperative lymphocyte-albumin-monocyte index as an inflammation- and nutrition-based predictor of overall survival in triple-negative breast cancer: A retrospective cohort study.